drugset
drugset / Trial / NCT02932462

Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis

NCT02932462 ↗

Phase 3 Completed 373 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomized Double-Blind, Vehicle-Controlled, Parallel Design, Multiple-Site, Phase III Clinical Study

Timeline

Start
2016-03
Primary completion
2016-12-01
Completion
2017-09-29

Outcome

Missed primary endpoint

registry analysis (superiority test); DSXS 1535 vs Placebo; p = 0.4557; Cochran-Mantel-Haenszel NCT02932462 ↗

registry analysis (superiority test); DSXS 1535 vs Placebo; p = 0.8096; Cochran-Mantel-Haenszel NCT02932462 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject DSXS Unknown — Topical

Indications

psoriasis